Drug
Homoharringtonine clinical trials
Also written Homoharringtonine, omacetaxine mepesuccinate and CGX-635.
Keep track of what changes. Save the Homoharringtonine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Other names
Combined with it in one product
Studies by the year they started
41 studies that test it; most in 2024 (6)
| Year | Studies |
|---|---|
| 1994 | 1 |
| 1998 | 1 |
| 1999 | 2 |
| 2000 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 6 |
| 2025 | 4 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 36
Institute of Hematology & Blood Diseases Hospital, China (5) · First Affiliated Hospital of Zhejiang University (5) · Teva Branded Pharmaceutical Products R&D, Inc. (4) · M.D. Anderson Cancer Center (4) · National Cancer Institute (NCI) (4) · The University of Hong Kong (2) · ChemGenex Pharmaceuticals (2) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (2)
Often tested with
Tested in the same studies.
Cytarabine (11) · Azacitidine (8) · Venetoclax (8) · Lisaftoclax (4) · Daunorubicin (4) · Decitabine (4) · Filgrastim (4) · Aclarubicin (3)
Studies
Open first, then newest update. How each study uses Homoharringtonine is read from its arms, and is right about nine times in ten.
Testing it · 42
- Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy FailureEnrolling by invitationPhase 2Guangdong Second Provincial General HospitalNCT07813390Written as homoharringtonine
- Intermediate-dose HAD Regimen for CEBPA Double-mutated AMLRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06529250Written as HAD
- MRD-positive AML Clinical StudyRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07131059Written as Homoharringtonine
- Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid LeukemiaRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06265545Written as Homoharringtonine
- Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive ChemotherapyEnrolling by invitationPhase 2/3First Affiliated Hospital of Zhejiang UniversityNCT07651163Written as Lisaftoclax+homoharringtonine+cytarabine+aclarubicin
- Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive ChemotherapyEnrolling by invitationPhase 2/3First Affiliated Hospital of Zhejiang UniversityNCT07651176Written as Lisaftoclax+homoharringtonine+cytarabine+aclarubicin
- VAH vs VA in Newly Diagnosed Elderly AMLNot yet recruitingPhase 3Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineNCT07469046Written as Homoharringtonine
- Safety and Efficacy of Docetaxel, Darolutamide, and Homoharringtonine Combined With Androgen Deprivation Therapy in Neoadjuvant Treatment of High-Risk Prostate Cancer: A Multicenter Prospective, Single-Arm Clinical StudyNot yet recruitingEarly Phase 1Zhongda HospitalNCT07516704Written as Docetaxel+ Darolutamide + Homoharringtonine+ Androgen Deprivation Therapy
- Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML PatientsNot yet recruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT07505160Written as Homoharringtonine
- Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.RecruitingPhase 2Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineNCT06483906Written as Venetoclax, Azacitidine and Homoharringtonine
- Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical StudyRecruitingPhase 2baotai LiangNCT07163910Written as homoharringtonine
- Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell LymphomaNot yet recruitingPhase 1/2First Affiliated Hospital of Zhejiang UniversityNCT07159906Written as Homoharringtonine
- Newly-diagnosed Pediatric T-cell ALL ProtocolRecruitingPhase 2/3Institute of Hematology & Blood Diseases Hospital, ChinaNCT06855810Written as homoharringtonine
- Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALLRecruitingPhase 3First Affiliated Hospital of Zhejiang UniversityNCT06361329Written as Homoharringtonine
- Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AMLRecruitingPhase 2Children's Hospital of Soochow UniversityNCT06221683Written as Homoharringtonine
- Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AMLRecruitingPhase 2/3The First Affiliated Hospital of Soochow UniversityNCT05805098Written as Homoharringtonine
- Omacetaxine + Azacitidine in Untreated Patients With High Grade MDSActive, not recruitingPhase 1/2University of Colorado, DenverNCT03564873Written as Omacetaxine
- HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AMLActive, not recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT06744556Written as Homoharringtonine
- Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)CompletedPhase 1University of Illinois at ChicagoNCT04926285Written as Omacetaxine
- Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid LeukemiaCompletedPhase 2First Affiliated Hospital of Zhejiang UniversityNCT05906914Written as cladribine + homoharringtonine + cytarabine
See all 42 studies that test Homoharringtonine →
Given in every arm · 6 — Homoharringtonine is usual care beside what is tested
- VHAG in Treating R/R T-ALL/LBLRecruitingPhase 2First Affiliated Hospital of Zhejiang UniversityNCT06742463Written as homoharringtonine
- Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid LeukemiaRecruitingPhase 3Shanxi Bethune HospitalNCT05726110Written as Homoharringtonine
- Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) PatientsNot yet recruitingNot applicableThe First Affiliated Hospital of Soochow UniversityNCT05805072Written as Homoharringtonine
- Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1TerminatedPhase 1/2M.D. Anderson Cancer CenterNCT04874194Written as Omacetaxine Mepesuccinate
- Study of Azacitidine Combined With Homoharringtonie Based Regimens in AMLStatus unknownPhase 2Ge ZhengNCT04248595Written as Homoharringtonine
- AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML PatientsTerminatedPhase 1/2University of Illinois at ChicagoNCT02440568Written as Omacetaxine mepesuccinate
As the comparator · 1 — what is tested is compared with Homoharringtonine
Codes
What other systems call Homoharringtonine · ClinicalTrials.gg INT006810
- MeSH (NLM) D000077863HomoharringtonineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 6FG8041S5BOMACETAXINE MEPESUCCINATEConfirmed FDA, NLM, Wikidata
- RxNorm 27100Confirmed FDA, Wikidata
- Wikidata Q7089373(-)-homoharringtonineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1127Omacetaxine MepesuccinateConfirmed FDA, Wikidata
- DrugBank DB04865One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077863 | Homoharringtonine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 6FG8041S5B | OMACETAXINE MEPESUCCINATE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 27100 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7089373 | (-)-homoharringtonine | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1127 | Omacetaxine Mepesuccinate | Confirmed FDA, Wikidata |
| DrugBank | DB04865 | — | One source Wikidata |
Also registered as omacetaxine (UNII 84MI6OYN4Z · RxNorm 1546446).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.